Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393850 | 0.87 | ACHE (0.40) | NPC1SMN1; SMN2SLC6A2SLC6A4MPO | |
| SCHEMBL4391454 | 0.86 | SMN1; SMN2 (0.45) | NPC1SMN1; SMN2HTR2ASLC6A4CDK4 | |
| SCHEMBL4397673 | 0.84 | SMN1; SMN2 (0.44) | NPC1SMN1; SMN2HTR2ASLC6A4CDK4 | |
| SCHEMBL4394022 | 0.83 | NPC1 (0.38) | PTGS2NPC1SMN1; SMN2SLC6A4CDK4 | |
| SCHEMBL4389267 | 0.82 | CDK4 (0.39) | PTGS2NPC1SMN1; SMN2SLC6A4CDK4 | |
| SCHEMBL4381230 | 0.81 | CDK4 (0.43) | SLC6A2HTR2ASLC6A4MPOCDK4 | |
| SCHEMBL4387834 | 0.80 | CDK4 (0.47) | CDK4CCND1 | |
| SCHEMBL4388577 | 0.79 | PTGS2 (0.40) | PTGS2SPRSLC6A2HTR2A | |
| SCHEMBL4389645 | 0.79 | PTGS2 (0.43) | PTGS2SPRSLC6A2HTR2AMPO | |
| SCHEMBL4388601 | 0.77 | SLC6A4 (0.47) | NPC1SMN1; SMN2SLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893575-B1 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H LUNDBECK AS (DK) | 2017-01-11 | — | — | EP | disclosed |
| US-7629473-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2009-12-08 | — | — | US | disclosed |
| EP-1893575-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H.Lundbeck A/S (DK) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134499-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | CYP11B2, CYP1A2, CYP4B1 | PTGS2 1170/4885NPC1 442/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.